Research programme: serotonin 1A/dopamine agonists - Bayer

Drug Profile

Research programme: serotonin 1A/dopamine agonists - Bayer

Alternative Names: Serotonin 1A/dopamine agonists research programme - Bayer

Latest Information Update: 26 Mar 2010

Price : $50

At a glance

  • Originator Bayer
  • Class
  • Mechanism of Action Dopamine receptor agonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 26 Mar 2010 Discontinued - Preclinical for Parkinson's disease in Germany (unspecified route)
  • 19 Mar 2001 Preclinical development for Parkinson's disease in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top